EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische Studie

A non-randomized phase 2 trial of pembrolizumab in untreated patients with carcinoma of unknown primary site

Jose G Monzon, Hatim Karachiwala, John Walker, Rakesh Goel, Paul Wheatley-Price, Timothy R Asmis, Vishal Navani, Patricia A Tang, Michael M Vickers

European Journal of Cancer · 2026-05 · 239 · 116709

DOI: 10.1016/j.ejca.2026.116709 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2026-05. Verfasst von Jose G Monzon und 8 weiteren Autor:innen. Beteiligte Einrichtung: Arthur JE Child Comprehensive Cancer Centre, University of Calgary, 3395 Hospital Dr NW, Calgary, AB T2N 4N1, Canada. Electronic address: jose.monzon…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Neoplasms, Unknown Primary, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Merck Canada Inc, Merck.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedNeoplasms, Unknown PrimaryAntineoplastic Agents, ImmunologicalHumansMaleFemaleAgedMiddle AgedAdultAged, 80 and overYoung AdultProgression-Free Survival

Stichwörter der Autor:innen

CUPImmunotherapyPD-L1Pembrolizumab

Substanzen

pembrolizumabAntibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Arthur JE Child Comprehensive Cancer Centre, University of Calgary, 3395 Hospital Dr NW, Calgary, AB T2N 4N1, Canada. Electronic address: jose.monzon@albertahealthservices.ca.
  • Arthur JE Child Comprehensive Cancer Centre, University of Calgary, 3395 Hospital Dr NW, Calgary, AB T2N 4N1, Canada.
  • Cross Cancer Institute, University of Alberta, 11560 University Ave, Edmonton, AB T6G 1Z2, Canada.
  • The Ottawa Hospital Cancer Centre, University of Ottawa, 501 Smyth Road, Ottawa, ON K1H 8L6, Canada.

Förderung

  • Merck Canada Inc
  • Merck

Zitieren

APA

Monzon, J. G., Karachiwala, H., Walker, J., Goel, R., Wheatley-Price, P., Asmis, T. R., Navani, V., Tang, P. A., & Vickers, M. M. (2026). A non-randomized phase 2 trial of pembrolizumab in untreated patients with carcinoma of unknown primary site. European Journal of Cancer, 239, 116709. https://doi.org/10.1016/j.ejca.2026.116709

Vancouver

Monzon JG, Karachiwala H, Walker J, Goel R, Wheatley-Price P, Asmis TR, et al. A non-randomized phase 2 trial of pembrolizumab in untreated patients with carcinoma of unknown primary site. European Journal of Cancer. 2026;239:116709. doi:10.1016/j.ejca.2026.116709

BibTeX
@article{Monzon2026,
  author = {Monzon, Jose G and Karachiwala, Hatim and Walker, John and Goel, Rakesh and Wheatley-Price, Paul and Asmis, Timothy R and Navani, Vishal and Tang, Patricia A and Vickers, Michael M},
  title = {A non-randomized phase 2 trial of pembrolizumab in untreated patients with carcinoma of unknown primary site},
  journal = {European Journal of Cancer},
  year = {2026},
  volume = {239},
  pages = {116709},
  doi = {10.1016/j.ejca.2026.116709}
}
Kostenlos starten →